HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $20

Benzinga · 3d ago
HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $32 to $20.